2. Academic Validation
  3. Ras-Responsive Element Binding Protein 1 regulates survival of Group 3 medulloblastoma

Ras-Responsive Element Binding Protein 1 regulates survival of Group 3 medulloblastoma

  • bioRxiv. 2025 Jul 21:2025.07.16.665230. doi: 10.1101/2025.07.16.665230.
Meher Beigi Masihi,  Kendall R Chambers,  Richard A Friedman,  Sergey Pampou,  Brian L Gudenas,  Jacob Torrejon,  Catherine Lee,  Grace Furnari,  Lianne Q Chau,  Sajina Gc,  Yingxi Lin,  Owen S Chapman,  Patryk Skowron,  Livia Garzia,  Michael D Taylor,  Lukas Chavez,  Olivier Ayrault,  Paul A Northcott,  Charles Karan,  Robert J Wechsler-Reya
PMID: 40777316 DOI: 10.1101/2025.07.16.665230
Abstract

Medulloblastoma (MB) is the most common malignant pediatric brain tumor, and Group 3 (G3, MYC-driven) MB has the worst prognosis. Despite advances in molecular classification, oncogenic drivers of G3 MB remain poorly defined. To identify such drivers, we profiled transcription factor expression across MB subgroups. Our analysis revealed Ras-responsive element binding protein 1 (RREB1) as one of the most highly expressed transcription factors in G3 MB. RREB1 knockdown impaired cell proliferation in vitro and prolonged survival in orthotopic xenograft models, suggesting it plays a key role in regulating tumor growth. Mechanistically, RREB1 acts by enhancing transcription of TGF-β pathway genes. Upstream, RREB1 expression is controlled by c-MET signaling, and the Met Inhibitor SU11274 decreased RREB1 levels and MB cell viability. Local delivery of SU11274 in tumor-bearing mice suppressed RREB1 expression and extended survival. These results establish the c-MET/RREB1 axis as a critical oncogenic regulator and a promising therapeutic target in in high-risk MB.

Figures
Products